Pneumonia drug studied as potential booster for childhood leukemia treatment
NCT ID NCT03568994
First seen Jan 31, 2026 · Last updated May 20, 2026 · Updated 13 times
Summary
This early-phase trial tested whether adding the pneumonia drug atovaquone to standard chemotherapy is feasible for children and young adults with newly diagnosed acute myeloid leukemia (AML). The study enrolled 26 participants and focused on measuring drug levels in the blood and how often doses were skipped due to side effects. The goal was to gather information for future research, not to directly treat the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Baylor College of Medicine - Texas Childrens Hospital
Houston, Texas, 77030, United States
-
Johns Hopkins Medicine
Baltimore, Maryland, 21205, United States
Conditions
Explore the condition pages connected to this study.